Jerusalem Pharmaceutical Group Marks High Performance Achievement
Jerusalem Pharmaceuticals Group Group achieved exceptional financial results in 2025, including a cash dividend payout of 15% of share par value, doubling its capital, and bold expansion moves like establishing a factory in Saudi Arabia. As a leading player in the Palestinian and regional pharmaceutical sector, the group stands out as an economic driver, employing hundreds of workers and exporting to 27 countries—demonstrating its global competitiveness amid challenges.
Financial Performance Exceeds Expectations
At the ordinary general assembly meeting, shareholders approved the 2025 financial statements, which recorded record net sales of $48.95 million and net profits of $10.26 million. Shareholders' equity rose to $88.20 million, with total assets reaching $114.60 million—signaling robust financial stability to fuel future investments.
The meeting was attended by board members, Chairman Dr. Mohammed Masrouji, Group General Manager Rami Al-Qutob, a representative from the Ministry of Economy, the auditing firm, and a large number of shareholders.
Lucrative Dividends and Capital Boost
The assembly approved a $2.7 million cash dividend (15% of par value). In the extraordinary session, capital increased by $18 million through capitalizing retained earnings into bonus shares distributed proportionally, bringing the total to $36 million across 36 million shares.
Ambitious Regional Growth Strategy
These steps align with a five-year plan emphasizing innovation, launching over 18 new products, production enhancements, and export expansion. The group announced a new factory in the Kingdom of Saudi Arabia (70% group stake, 30% local investors), plus a scientific office in the UAE and upgrades to facilities in Palestine, Jordan, and Algeria. Chairman Dr. Mohammed Masrouji talked about challenges and opportunities for new ventures in other Arab countries, affirming the group's shift toward regional expansion.
Leading Position in the Pharmaceutical Market
Jerusalem Pharmaceutical Group leads as one of Palestine's largest and most expansive pharmaceutical companies, producing 370 diverse drug formulations exported to 27 countries worldwide, including the Middle East, Africa, and Europe. It employs thousands of skilled workers, playing a pivotal role in bolstering the Palestinian economy through exports, local innovation, and industrial development. This model exemplifies sustainability and leadership, balancing strong shareholder returns with long-term community value.